OncoFirm Diagnostics Corp. (a registered Delaware Corporation) Cancer Rapid Tests, we are in a premarket investment phase. Our mission will be in revolutionizing early rapid cancer diagnostics through cutting-edge Fluorescent Lateral Flow Tests (FLFTs) and traditional lateral flow assay (LFA) technology. Our proprietary rapid diagnostic solutions utilize various antigens, with highly specific biomarkers linked to cancer progression, to provide accurate, fast, and accessible screening tools. Available to hospitals, clinics, and diagnostic labs, cancer screening and progression programs, research in oncology and infectious diseases…                                       Investor Disclaimer (1)